SAN FRANCISCO, CA--(Marketwired - October 01, 2015) - Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. (
The Life Sciences Report: What sets BriaCell Therapeutics Corp.'s BriaVax apart from others in the field of immuno-oncology?
Dr. Charles Wiseman: Vaccine studies have been feasible for the past 75 to 100 years. The problem has been that vaccines produced sporadic responses, and we didn't have the tools to unlock the essence of the procedure. Today we have sophisticated tools, both for diagnosis and for manipulating the components to make vaccines. It is nice to see the surge of immunotherapy companies that are developing a variety of interesting techniques.
The initial program for BriaVax was designed as a safety trial in breast cancer, with six doses. Keep in mind that all the patients being tested were in the latest stages of cancer. Nevertheless, after three doses, the results showed…
Continue reading this interview: Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
BriaCell Therapeutics Corp. is a sponsor of Streetwise Reports. Dr. Wagner, Dr. Wiseman, and Dr. Babaei had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Wagner, Dr. Wiseman, and Dr. Babaei and not of The Life Sciences Report or its officers.
Contact Information:
Jim Patrick